Welcome to our dedicated page for Ocular Therapeut news (Ticker: OCUL), a resource for investors and traders seeking the latest updates and insights on Ocular Therapeut stock.
Ocular Therapeutix, Inc. (NASDAQ: OCUL) generates frequent news as an ophthalmology-focused biopharmaceutical company advancing late-stage retinal programs and a commercial eye-care product. Its press releases highlight progress across the AXPAXLI (OTX-TKI) clinical programs in wet age-related macular degeneration (wet AMD) and non-proliferative diabetic retinopathy (NPDR), as well as updates related to DEXTENZA, financings, and corporate events.
News coverage for OCUL commonly includes clinical milestones such as target randomization in the SOL-R Phase 3 wet AMD trial, completion of randomization in SOL-1, and the initiation or advancement of the HELIOS Phase 3 registrational program in NPDR. The company also issues announcements about regulatory strategy, including Special Protocol Assessment (SPA) agreements with the U.S. Food and Drug Administration for SOL-1 and HELIOS-2 and plans to leverage the 505(b)(2) pathway for AXPAXLI in wet AMD.
Investors following OCUL news will see regular business and capital markets updates, such as underwritten equity offerings, cash runway disclosures, and inducement equity grants under Nasdaq Listing Rule 5635(c)(4). The company also reports quarterly financial results and business highlights, describing clinical execution, trial timelines, and planned extension studies like SOL-X for long-term evaluation of AXPAXLI in wet AMD.
In addition, Ocular Therapeutix announces participation in scientific and investor conferences, where it presents data from earlier-stage trials (for example, HELIOS Phase 1 results in NPDR) and discusses its strategy to "redefine the retina experience." For a consolidated view of these developments, the OCUL news page on Stock Titan brings together clinical, regulatory, financial, and corporate communications so readers can track how trial outcomes, regulatory interactions, and financing activities may shape the company’s ophthalmic pipeline and commercial portfolio over time.
Ocular Therapeutix (NASDAQ: OCUL) appointed David W. Robinson as Global Chief Commercial Officer effective Jan 21, 2026. Robinson brings deep retina launch experience, including a lead role on the EYLEA launch and recent service as Chief Marketing Officer, Global Ophthalmology at Merck. He will report to Pravin U. Dugel and join the Executive Leadership Team, leading the global commercial franchise and launch readiness for AXPAXLI (OTX-TKI) for wet AMD and NPDR, if approved. Steve Meyers will continue as Chief Commercial Officer and collaborate on AXPAXLI while leading DEXTENZA marketing.
Ocular Therapeutix (NASDAQ: OCUL) intends to submit an NDA for AXPAXLI in wet AMD shortly after positive year‑one SOL‑1 topline data, which are on track for 1Q 2026. The company plans to leverage the 505(b)(2) pathway and cites an existing SPA and a superiority trial design versus aflibercept to support an accelerated review. Ocular says AXPAXLI could be the first TKI commercialized for wet AMD with potential durability up to 12 months. The company will continue SOL‑1 into year two and run SOL‑R and SOL‑X to provide additional data for clinicians and payors.
Ocular Therapeutix (NASDAQ: OCUL) granted inducement equity awards to eight newly hired non-executive employees under its 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The awards, effective December 1, 2025, consist of non-statutory stock options to purchase an aggregate of 51,600 shares and restricted stock units representing an aggregate of 17,066 shares. The stock options carry a $11.71 exercise price (closing Nasdaq price on the effective date), have a 10-year term, and vest over four years (25% after one year, then monthly over three years). The restricted stock units vest over three years in equal annual installments, with the first vesting on December 1, 2026. Awards are subject to the award agreements and the inducement plan terms.
Ocular Therapeutix (NASDAQ: OCUL) announced the first patient randomized in HELIOS-3, the second Phase 3 registrational trial for AXPAXLI (OTX-TKI) in non-proliferative diabetic retinopathy (NPDR) on Nov 24, 2025. HELIOS-2 and HELIOS-3 are complementary global superiority studies using a novel ordinal ≥2-step diabetic retinopathy severity score (DRSS) primary endpoint, with primary assessment at Week 52. HELIOS-2 compares AXPAXLI dosed every 12 months to ranibizumab 0.3 mg; HELIOS-3 compares 6- and 12-month AXPAXLI regimens to sham. Ocular secured an SPA alignment with the FDA on the novel DRSS endpoint for HELIOS-2 and is targeting a broad DR label by including patients with non-center-involved DME (non-CI-DME).
Ocular Therapeutix (NASDAQ: OCUL) will participate in investor conferences in November and December 2025 with fireside chats by Pravin U. Dugel, MD, Executive Chairman, President and CEO.
Event details: Jefferies Global Healthcare Conference in London — Tuesday, November 18, 2025, 2:30–2:55 PM GMT; Piper Sandler 37th Annual Healthcare Conference in New York — Wednesday, December 3, 2025, 8:30–8:55 AM ET. Live webcasts will be available on the company's Investor Relations Events and Presentations page, and replays will be archived for at least 30 days after each presentation.
Ocular Therapeutix (NASDAQ: OCUL) granted inducement equity awards to a newly hired non-executive employee under its 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The grants, effective November 3, 2025, include a non-statutory stock option for 1,100 shares at an exercise price of $11.47 (the closing price on the grant date) with a 10-year term and four-year vesting (25% vesting on October 20, 2026, then monthly over three years), and a restricted stock unit award for 367 shares vesting in equal annual installments over three years beginning November 3, 2026. Awards are subject to the award agreements and plan terms.
Ocular Therapeutix (NASDAQ: OCUL) reported Q3 2025 results and program milestones on Nov 4, 2025. The company held $344.8 million cash as of Sept 30, 2025 and closed an equity offering in Oct 2025 with approximately $445 million net proceeds, providing projected runway into 2028.
Clinical progress: the SOL-R wet AMD registrational trial achieved target randomization of 555 subjects (topline on track for 1H 2027); SOL-1 superiority trial remains on track for Q1 2026 topline with >95% retention; HELIOS Phase 3 program in NPDR is imminent and has an SPA-aligned novel ordinal DRSS endpoint. Q3 revenue was $14.5M (down 5.8% YoY) with a net loss of $69.4M (−$0.38 per share).
Ocular Therapeutix (NASDAQ: OCUL) announced that its Phase 3 SOL-R trial of AXPAXLI (OTX-TKI) in wet age-related macular degeneration has reached its target randomization of 555 subjects. SOL-R compares AXPAXLI every 6 months versus aflibercept (2 mg) every 8 weeks across ~100 sites in the U.S., Argentina, India and Australia, with a Week 56 primary endpoint for mean change in BCVA and 90% power to a non-inferiority margin of -4.5 letters. Topline data remain on track for 1H 2027. Together with SOL-1 (single-injection superiority study; topline expected Q1 2026), these trials could support a potential NDA for AXPAXLI if both readouts are positive.
Ocular Therapeutix (NASDAQ: OCUL) announced it will report third quarter 2025 financial results and host a conference call and webcast on Tuesday, November 4, 2025 at 8:00 AM ET.
Participant dial-in numbers are U.S.: 1-877-407-9039 and International: 1-201-689-8470. A live webcast will be available on the company’s Investor Relations Events and Presentations page, and a replay will be archived for at least 30 days.
Ocular Therapeutix (NASDAQ: OCUL) will participate in multiple scientific conferences in October 2025 to present clinical and company data on retina therapies.
Key appearances: American Academy of Optometry (Boston, Oct 8–11) — poster on one‑year HELIOS Phase 1 OTX‑TKI safety and efficacy on Oct 9, 4:30–6:30 PM ET by Trung Tran; Eyecelerator @ AAO (Orlando, Oct 16) — company showcase by Peter K. Kaiser, MD on Oct 16, 1:15–2:45 PM ET; American Academy of Ophthalmology (Orlando, Oct 18–20) — on‑demand poster on macular fluid and vascular leakage after a single axitinib intravitreal hydrogel, presented by Margaret Chang, MD, MS. Exact times may change.
FAQ
What is the current stock price of Ocular Therapeut (OCUL)?
What is the market cap of Ocular Therapeut (OCUL)?
